echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Baiji Shenzhou announced the global tumor strategic cooperation and equity investment with Amgen

    Baiji Shenzhou announced the global tumor strategic cooperation and equity investment with Amgen

    • Last Update: 2020-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Baiji Shenzhou today announced that the global tumor strategic cooperation reached with Amgen on October 31, 2019 has been approved by the company's shareholders and meets other transaction conditions, and the cooperation has come into effect At the same time, Amgen has completed the acquisition of about 20.5% shares in Baiji Shenzhou Cambridge, Ma and Beijing, China January 2, 2020 / AP / -- Baiji Shenzhou (NASDAQ Code: bgne; Hong Kong stock exchange code: 06160), is a biomedical company in the commercial stage, focusing on the development and commercialization of innovative molecular targets for cancer treatment and tumor immune drugs Baiji Shenzhou today announced that the global tumor strategic cooperation reached with Amgen on October 31, 2019 has been approved by the company's shareholders and meets other transaction conditions, and the cooperation has come into effect At the same time, Amgen has completed the acquisition of about 20.5% shares in Baiji Shenzhou According to the terms of cooperation, Baiji Shenzhou will be responsible for the commercialization and development in China of Amgen's three approved or declared cancer drugs, namely, agavir (xgeva ®) desumab injection, kyprolis (kafzomib for injection) and blincyto (bilintomolobib for injection) Baiji Shenzhou and Amgen will cooperate to develop 20 Amgen anti-tumor pipeline drugs under research, among which Baiji Shenzhou will be responsible for the development and commercialization in China Amgen purchased 15895001 Baiji Shenzhou ADSS (representing 206635013 common shares) with cash value of about $2.8 billion In addition, Baiji Shenzhou also announced that Mr Anthony C Hooper, former executive vice president of Amgen global business operations, was elected as a member of the board of directors of the company according to the relevant agreement on share acquisition, effective today Mr Hooper joined Amgen as executive vice president of global business operations in October 2011 and retired from the company until August 2018 Prior to that, Mr Hooper served for 15 years at Bristol Myers Squibb, most recently as senior president of global business operations and President of its pharmaceutical industry in the Americas, Japan and intercontinental regions Mr Hooper's previous work experience includes assistant vice president of global marketing at Wyeth and the international marketing department that leads Lederle international Mr Ou Lei Qiang, chairman, founder and CEO of Baiji Shenzhou, said: "we are very pleased to start the development of Amgen's important anti-tumor drugs and product pipeline to help patients around the world who may benefit from these drugs Through this strategic cooperation, we also warmly welcome Tony Hooper to join the board of directors of the company Tony is committed to serving patients He has accumulated many years of commercial experience in large-scale enterprises, which can help Baiji Shenzhou's next enterprise growth and business operation expansion " Mr Hooper commented: "in the context of China's drug reform, Baiji has created a unique global model for the development of new cancer drugs, which can have a positive impact on the pharmaceutical industry and patients After spending some time with the baiji Shenzhou team, I was deeply impressed by their insight, creativity and firm belief in bringing high-quality treatment programs to patients " About Baiji Shenzhou, a global, commercial stage, R & D-based biotechnology company, focusing on the research and development of molecular targeting and immunotherapy for tumor At present, Baiji Shenzhou has more than 3300 employees in mainland China, the United States, Australia and Switzerland, and its research product line includes new oral small molecule and monoclonal antibody anti-cancer drugs At present, Baiji Shenzhou is also building a drug combination program for anti-cancer treatment, aiming to bring lasting and far-reaching impact on the life of cancer patients Baichi sells its own Btk inhibitor brukinsa in the United States Gamma (zebudinib); in China, its anti-pd1 antibody drug baizean ® (tirelizumab) has been approved for marketing Under the authorization of Xinji Logistics Co., Ltd (which belongs to Bristol Myers Squibb), Baiji Shenzhou will sell Abraxane ® paclitaxel for injection (albumin binding type), refumex ® (lenalidomide) and vidasha ® (azacytidine for injection) in China; under the authorization of Amgen, Baiji Shenzhou plans to sell angavi ® (xgeva ®) desurmab injection in China [1], [2] Baiji Shenzhou forward looking statement This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including the plans and potential commercialization of the related development programs, responsibilities of both parties, and And potential benefits of cooperation Due to various important factors, the actual results may be significantly different from the forward-looking statements These factors include the following risks: the ability of Baiji Shenzhou to prove the efficacy and safety of the candidate drugs; the clinical results of the candidate drugs may not support further development or market approval; the actions of the drug administration department may affect the start, schedule and progress of the clinical trials and the market approval of the products; the market products and drug candidates of Baiji Shenzhou (if available (b) the ability to achieve commercial success; the ability of Baiji Shenzhou to obtain and maintain its technology and drug intellectual property protection; the dependence of Baiji Shenzhou on third parties for drug development, production and other services; the limited operating history of Baiji Shenzhou and the ability to obtain further working capital to complete the development and commercialization of candidate drugs; and the latest quarterly report of Baiji Shenzhou The various risks discussed more fully in the "risk factors" section of form 10-Q of the report, as well as the discussion of potential risks, uncertainties and other important factors in baichi's future report to the securities and Exchange Commission All information in this press release is limited to the date of release, and unless required by law, baichi shall not be responsible for updating such information Penicillin is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.